Table 2.
Disease characteristics of young and middle-aged mg patients (n = 145).
| Variable | n (%)/ Mean ± SD | Variable | n (%) |
|---|---|---|---|
| MGFA clinical type | Follow-up Frequency | ||
| Ocular MG | 50 (34.5) | Monthly | 18 (12.5) |
| Generalized MG | 95 (65.5) | Every 3 months | 73 (50.3) |
| Disease duration (years) | Every 6 months | 37 (25.5) | |
| <5 | 65 (44.8) | Yearly or less | 17 (11.7) |
| 5–30 | 80 (55.2) | Reason for No Regular Follow-up | |
| Initial major symptom | Too busy | 39 (26.9) | |
| Ptosis | 51 (35.2) | Forgot | 67 (46.2) |
| Limb weakness | 29 (20.0) | Negative psychology | 31 (21.4) |
| Generalized weakness | 62 (42.8) | Objective reasons | 8 (5.5) |
| Dyspnea | 3 (2.0) | Experience of Pain | |
| Current major symptom | No | 74 (51.0) | |
| Ptosis | 50 (34.5) | Yes | 71 (49.0) |
| Limb weakness | 37 (25.5) | Pain Location (n = 71) | |
| Generalized weakness | 49 (33.8) | Head | 10 (14.1) |
| Dyspnea | 9 (6.2) | Trunk | 44 (62.0) |
| MG quantitative score | 8.26 ± 7.78 | Limbs | 17 (23.9) |
| Primary treatment | Comorbidities | ||
| Surgery only | 5 (3.4) | No | 105 (72.4) |
| Medication + Surgery | 16 (11.1) | Yes | 40 (27.6) |
| Medication only | 124 (85.5) | Type of Comorbidity (n = 40) | |
| Medication type (Multiple choices, n = 140) | Hyperthyroidism | 24 (60.0) | |
| Immunosuppressants | 54 (38.6) | Hypothyroidism | 11 (27.5) |
| AChE inhibitors (e.g., Pyridostigmine) | 134 (95.7) | Thymoma | 5 (12.5) |
| Corticosteroids | 51 (36.4) | Hospitalization due to MG | |
| Regular follow-up | No | 102 (70.3) | |
| No | 39 (26.9) | Yes | 43 (29.7) |
| Yes | 106 (73.1) | Myasthenic Crisis | |
| No | 120 (82.8) | ||
| Yes | 25 (17.2) |